Pharma Report 2012: Get Back in Shape

Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

19    Otsuka    $5.2B    up 13.0%
Global revenue*: $13.1B (16th); down 2.2% 

R&D spend*: $2.0B (15th), up 11.7%; 14.5% of rev.

Top brands: Abilify ($5.2B), Samsca ($48M), Busulfex ($12M), Pletal ($2M)

Planned launches: Sativex (pain)

Promotional spend: $15M (19th); 0.3% of rev.

Patent expirations: Abilify (2015)

The Japanese holding company remains dependent upon its blockbuster antipsychotic drug Abilify, which it co-promotes with Bristol-Myers Squibb. In the fiscal year ending March 31, 2011, the drug provided half of the company's income. Otsuka says its goal is to continue to focus on teaming up with companies for research, with an emphasis on CNS and oncology. The company also noted that the earthquake that rocked Japan and toppled several warehouses did not significantly affect business.
* Global revenue and R&D spend are based on the fiscal year ending March 31, 2011, the latest data available at press time.

Back to first page

Page 19 of 21
You must be a registered member of MMM to post a comment.

Next Article in Features

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters

Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.